GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » ROE % Adjusted to Book Value

IBRX (ImmunityBio) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio ROE % Adjusted to Book Value?

ImmunityBio's ROE % for the quarter that ended in Sep. 2024 was 0.00%. ImmunityBio's PB Ratio for the quarter that ended in Sep. 2024 was N/A. ImmunityBio's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

ImmunityBio ROE % Adjusted to Book Value Historical Data

The historical data trend for ImmunityBio's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio ROE % Adjusted to Book Value Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
- - - - -

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ImmunityBio's ROE % Adjusted to Book Value

For the Biotechnology subindustry, ImmunityBio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunityBio's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunityBio's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where ImmunityBio's ROE % Adjusted to Book Value falls into.


ImmunityBio ROE % Adjusted to Book Value Calculation

ImmunityBio's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

ImmunityBio's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmunityBio ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of ImmunityBio's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunityBio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
RVMD NTLA XENE BHVN PRTA CRNX ZLAB IDYA CBAY FTRE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
26CA:Germany
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
Website
https://www.immunitybio.com
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
Executives
Patrick Soon-shiong director, 10 percent owner, officer: See remarks 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Cambridge Equities, Lp 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Mp 13 Ventures, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Michael D Blaszyk director C/O NANTKWEST, INC., 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
John Owen Brennan director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Wesley Clark director C/O ARGYLE SECURITY ACQUISITION CORP., 200 CONCORD PLAZA, SUITE 700, SAN ANTONIO TX 78216
Regan J Lauer officer: Chief Accounting Officer 4250 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Richard Adcock officer: Chief Executive Officer C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Christobel Selecky director C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David C. Sachs officer: Chief Financial Officer C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Frederick W Driscoll director